A federal advisory committee voted Thursday to soften rules on seven peptides, including BPC-157 and TB-500. The vote was tight. It is non-mandatory. The FDA has given no indication on whether it will adopt the suggestion. The move came after weeks of stakeholder sessions. Wellness backers pressed strongly for wider access. RFK Jr. was among them. Critics say these compounds have no solid safety track record or help for most uses. The call could reshape how the agency handles a part of the wellness market that is expanding rapidly. Regulators are watching to see if the agency takes up the plan. A representative for the agency offered no clear schedule for a next move. Industry voices argue the change would widen access to substances some say help. Critics warn that looser rules could allow poor oversight across a barely regulated market. The advisory vote only opens the door to a change, and the ultimate call rests with the federal regulator.